Zhang Wei, Chen Jing, He Guoqian, Xu Wenming, He Guolin
Department of medical oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Cancer Hospital affiliate to School of Medicine.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education.
Medicine (Baltimore). 2020 Aug 28;99(35):e22045. doi: 10.1097/MD.0000000000022045.
Previous studies have reported that microRNA-21 (mRNA-21) has an effect on the prognosis of pancreatic cancer. However, the conclusion is still unclear. Therefore, this study will try to explore the effect of high expression of mRNA-21 on the prognosis of pancreatic cancer.
Retrieved the database, including the China National Knowledge Infrastructure (CNKI), Chinese Biomedical literature Database (CBM), Chinese Scientific and Journal Database (VIP), Wan Fang database, PubMed, and EMBASE. Hazard ratios (HRs) and its 95% confidence intervals (CIs) to assess the prognostic effect of miRNA-21 on overall survival (OS) and disease-free survival (DFS). RevMan 5.3 and STATA 16.0 software were used to perform the meta-analysis.
This study will comprehensively review and evaluate the available evidence of high expression of miRNA-21 on the prognosis of patients with pancreatic cancer.
Our findings will show the effect of high expression of miRNA-21 on the prognosis of patients with pancreatic cancer. Such studies may find a new prognostic marker for patients with pancreatic cancer and help clinicians and health professionals make clinical decisions.
The private information from individuals will not publish. This systematic review also will not involve endangering participant rights. Ethical approval is not available. The results may be published in a peer- reviewed journal or disseminated in relevant conferences.
DOI 10.17605/OSF.IO/2A6KJ.
既往研究报道微小RNA-21(miRNA-21)对胰腺癌预后有影响。然而,结论仍不明确。因此,本研究将尝试探讨miRNA-21高表达对胰腺癌预后的影响。
检索数据库,包括中国知网(CNKI)、中国生物医学文献数据库(CBM)、维普中文科技期刊数据库(VIP)、万方数据库、PubMed和EMBASE。采用风险比(HRs)及其95%置信区间(CIs)评估miRNA-21对总生存期(OS)和无病生存期(DFS)的预后影响。使用RevMan 5.3和STATA 16.0软件进行荟萃分析。
本研究将全面回顾和评估miRNA-21高表达对胰腺癌患者预后的现有证据。
我们的研究结果将显示miRNA-21高表达对胰腺癌患者预后的影响。此类研究可能为胰腺癌患者找到新的预后标志物,并帮助临床医生和卫生专业人员做出临床决策。
不会公布个人隐私信息。本系统评价也不会涉及危及参与者权利。无需伦理批准。结果可能发表在同行评审期刊上或在相关会议上传播。
DOI 10.17605/OSF.IO/2A6KJ。